Biocon’s recent acquisition of its partner Viatris Inc.'s biosimilar business has shocked the investors as the company’s shares fell nearly 12% on the bourses. Host Dia Rekhi along with Biocon Biologics’ Deputy CEO Shreehas Tambe, ET’s Kiran Somvanshi, and ET Prime’s Vikas Dandekar break down the deal means for the company and the investors and whether the $3.3-billion bet is worth the risk? Credits: ET Now